EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial

Hossein Kargar iD, Mohammad Ali Esfandiari iD, Mehdi Ghahartars iD, Mohammad Mahdi Parvizi iD

Clinical and Experimental Dermatology · 2026

DOI: 10.1093/ced/llag210 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Hossein Kargar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Sulfonamides, Hydroxychloroquine, Azetidines, Pyrazoles. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences, Arena Life Science company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lichen planus (LP) is a chronic autoimmune inflammatory disorder with limited effective long-term treatment options. Hydroxychloroquine has been widely used as systemic therapy, and although baricitinib, a Janus kinase 1/2 inhibitor, has shown promise in patients with refractory cases, comparative evidence is lacking.

Objectives

This study aimed to compare the efficacy and safety of baricitinib vs. hydroxychloroquine in patients with cutaneous LP.

Methods

In this randomized controlled trial, 32 patients with cutaneous LP were randomized to baricitinib 4 mg once daily or hydroxychloroquine 200 mg twice daily for 12 weeks. The primary outcome was the change in Lichen Planus Activity and Damage Index (LiPADI). Secondary outcomes included pruritus severity, patient satisfaction (each assessed using a 0–10 visual analogue scale) and Physician Global Assessment (PGA).

Results

Both groups showed significant improvement in pruritus severity and LiPADI scores (P < 0.001). Mean LiPADI scores decreased from 14.20 (SD 3.44) to 1.07 (SD 0.99) with baricitinib and from 12.18 (SD 3.28) to 5.27 (SD 2.28) with hydroxychloroquine (P = 0.03), indicating a greater reduction in disease activity with baricitinib. The pruritus visual analogue scale improved from 8.33 (SD 1.67) to 0.21 (SD 0.80) in the baricitinib group and from 8.81 (SD 1.66) to 3.27 (SD 1.01) in the hydroxychloroquine group (P < 0.001). Patient satisfaction increased from 4.46 (SD 0.83) to 8.78 (SD 1.12) and from 4.63 (SD 0.50) to 6.90 (SD 0.94), respectively (P = 0.001). PGA improved in both groups, but the between-group difference was not statistically significant (P = 0.38). No major or life-threatening adverse events were observed in both groups.

Conclusions

In this assessor-blinded randomized trial, both baricitinib and hydroxychloroquine improved cutaneous LP over 12 weeks. Baricitinib was associated with greater short-term improvement in disease activity and pruritus, along with higher patient satisfaction, without evidence of additional short-term safety concerns. The small sample size, short follow-up and nondouble-blind design warrant cautious interpretation. Large double-blind studies with longer follow-up are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesHydroxychloroquineAzetidinesPyrazolesLichen PlanusHumansFemalePurinesMiddle AgedMaleAdultTreatment OutcomePatient SatisfactionSeverity of Illness IndexPruritusAged

Substanzen

baricitinibSulfonamidesHydroxychloroquinePurinesAzetidinesPyrazoles

Autor:innen und Institutionen

  • Department of Dermatology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Hossein Kargar, Mohammad Ali Esfandiari, Mehdi Ghahartars, Mohammad Mahdi Parvizi

Förderung

  • Shiraz University of Medical Sciences
  • Arena Life Science company

Zitieren

APA

Kargar, H., Esfandiari, M. A., Ghahartars, M., & Parvizi, M. M. (2026). Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag210

Vancouver

Kargar H, Esfandiari MA, Ghahartars M, Parvizi MM. Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag210

BibTeX
@article{Kargar2026,
  author = {Kargar, Hossein and Esfandiari, Mohammad Ali and Ghahartars, Mehdi and Parvizi, Mohammad Mahdi},
  title = {Baricitinib vs. hydroxychloroquine for cutaneous lichen planus: an assessor-blind randomized controlled trial},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag210}
}
Kostenlos starten →